List of Figures

Figure 2.1	Growth of cells	14
Figure 2.2	Nanoparticulate platforms for the targeted and controlled delivery of drugs, (a) liposome, (b) polymeric nanoparticle, (c) lipid polymer hybrid nanoparticle and (d) dendrimer.	37
Figure 2.3	Particle schematics, (A) nanosphere, (B) nanocapsule (C) liposome, (D) micelle, (E) dendrimers functionalized with completed (left) and encapsulated drug molecules.	38
Figure 2.4	Targeted particles: (A) example of a folate receptor targeted particle. Liposome functionalized with PEG tethers to impart STEALTH characteristics and folate for tumor targeting, (B) folate-conjugated PLGA-PGA polymeric micelle loaded with encapsulated doxorubicin and (C) cRGD-functionalized PCL–PEG polymeric micelle containing encapsulated doxorubicin.	48
Figure 2.5	Molecular structure of lactide and glycolide based biodegradable polymer	55
Figure 2.6	Different methods for preparation of PLGA NPs.	57
Figure 2.7	Degradation of polycaprolactone.	61
Figure 3.1	Regressed calibration curve of ATZ by HPLC at 215 nm. Data presented as Mean ± SD, n=3 (some error bars are too small to be shown).	93
Figure 3.2	Chromatogram of ATZ solution by HPLC at 215 nm.	94
Figure 3.3	Regressed calibration curve of EXE by HPLC at 247 nm. Data presented as Mean ± SD, n = 3 (some error bars are too small to be shown).	98
Figure 3.4	Chromatogram of EXE solution by HPLC at 247 nm.	99
Figure 4.1	FTIR spectra of polymers, A: PLGA; B: PEG and C: PLGA-PEG.	127
Figure 4.2	NMR spectra of pegylated PLGA.	128
Figure 4.3	Gel permeation chromatogram of pegylated PLGA.	128
Figure 4.4	FTIR spectra of cPCL.	129
Figure 4.5	Gel permeation chromatogram of cPCL.	130

Figure 4.6	FTIR spectra of polymers, A: cPCL; B: PEG and C: PCL-PEG.	131
Figure 4.7	NMR spectra of pegylated PCL.	131
Figure 4.8	Gel permeation chromatogram of pegylated PCL.	132
Figure 4.9	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of ATZ loaded PLGA NPs.	140
Figure 4.10	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of ATZ loaded PLGA NPs.	140
Figure 4.11	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of ATZ loaded PLGA NPs.	141
Figure 4.12	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of ATZ loaded PLGA NPs.	141
Figure 4.13	Particle size distribution of ATZ loaded PLGA NPs	142
Figure 4.14	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of ATZ loaded cPCL NPs.	152
Figure 4.15	Contour plots showing effect of (a) X_1 vs X_2 (at -1 level of X_3), (b) X_1 vs X_3 (at -1 level of X_2) and () X_2 vs X_3 (at -1 level of X_1) on PS of ATZ loaded cPCL NPs.	152
Figure 4.16	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of ATZ loaded cPCL NPs.	153
Figure 4.17	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of ATZ loaded cPCL NPs.	153
Figure 4.18	Particle size distribution of ATZ loaded cPCL NPs	154
Figure 4.19	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of EXE loaded PLGA NPs.	163
Figure 4.20	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of	163

	X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of EXE loaded PLGA NPs.	
Figure 4.21	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of EXE loaded PLGA NPs.	165
Figure 4.22	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of EXE loaded PLGA NPs.	165
Figure 4.23	Particle size of EXE loaded PLGA NPs	175
Figure 4.24	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of EXE loaded cPCL NPs.	175
Figure 4.25	Contour plots showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of EXE loaded cPCL NPs.	175
Figure 4.26	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PDE of EXE loaded cPCL NPs.	176
Figure 4.27	Response surface plot showing effect of (A) X_1 vs X_2 (at -1 level of X_3), (B) X_1 vs X_3 (at -1 level of X_2) and (C) X_2 vs X_3 (at -1 level of X_1) on PS of EXE loaded cPCL NPs.	176
Figure 4.28	Particle size distribution of EXE loaded cPCL NPs	177
Figure 4.29	Zeta potential of ATZ loaded PLGA NPs	179
Figure 4.30	TEM image of ATZ loaded PLGA NPs	180
Figure 4.31	DSC thermogram of ATZ (A), ATZ loaded PLGA NPs (B), Sucrose (C), PLGA (D) and Physical mixture (E).	181
Figure 4.32	Drug release profile of ATZ from plain drug suspension, PLGA NPs and pegylated PLGA NPs across semi-permeable membrane using the dialysis bag diffusion technique in phosphate buffered saline (pH 7.4). The values represent mean ± S.D. of three batches.	182
Figure 4.33	Effect of different storage conditions on drug content and PS of ATZ loaded PLGA NPs.	183

Figure 4.34	Zeta potential of ATZ loaded cPCL NPs	184
Figure 4.35	TEM image of ATZ loaded cPCL NPs	185
Figure 4.36	DSC thermogram of ATZ (A), ATZ loaded cPCL NPs (B), Sucrose (C), cPCL (D) and Physical mixture (E).	186
Figure 4.37	Drug release profile of ATZ from plain drug suspension, cPCL NPs and pegylated PCL NPs across semi-permeable membrane using the dialysis bag diffusion technique in phosphate buffered saline (pH 7.4). The values represent mean ± S.D. of three batches.	187
Figure 4.38	Effect of different storage conditions on drug content and PS of ATZ loaded cPCL NPs.	188
Figure 4.39	Zeta potential of EXE loaded PLGA NPs	189
Figure 4.40	TEM image of EXE loaded PLGA NPs	190
Figure 4.41	DSC thermogram of EXE loaded PLGA NPs (A), EXE (B), Sucrose (C), PLGA (D) and Physical mixture (E).	191
Figure 4.42	Drug release profile of EXE from plain drug suspension, PLGA NPs and pegylated PLGA NPs across semi-permeable membrane using the dialysis bag diffusion technique in phosphate buffered saline (pH 7.4). The values represent mean ± S.D. of three batches.	192
Figure 4.43	Effect of different storage conditions on drug content and PS of ATZ loaded cPCL NPs.	193
Figure 4.44	Zeta potential of EXE loaded cPCL NPs	194
Figure 4.45	TEM image of EXE loaded cPCL NPs	195
Figure 4.46	DSC thermogram of EXE loaded cPCL NPs (A), EXE (B), cPCL (C), Sucrose (D) and Physical mixture (E).	196
Figure 4.47	Drug release profile of EXE from plain drug suspension, PCL NPs and pegylated PCL NPs across semi-permeable membrane using the dialysis bag diffusion technique in phosphate buffered saline (pH 7.4). The values represent mean ± S.D. of three batches.	197
Figure 4.48	Effect of different storage conditions on drug content and PS of ATZ loaded cPCL NPs.	198

Figure 5.1	Phagocytic uptake histograms of 6-Coumarin loaded NP formulations by human acute monocytic leukemia cell line (THP1) after incubation for (a) 60, (b) 120 and (c) 240 min using FACS.	212
Figure 5.2	Phagocytic uptake of 6-Coumarin loaded PLGA and pegylated PLGA NPs using Human acute monocytic leukemia cell line, THP1 after incubation for 60, 120 and 240 min using FACS. Data presented as Mean ± SD, n=3	212
Figure 5.3	Drug release profile of ATZ from plain drug suspension, PLGA NPs and pegylated PLGA NPs across semi-permeable membrane using the dialysis bag diffusion technique in phosphate buffered saline (pH 7.4). The values represent mean ± S.D. of three batches.	213
Figure 5.4	TEM image of ATZ loaded pegylated PLGA ImmunoNPs.	214
Figure 5.5	Phagocytic uptake histograms of 6-Coumarin loaded NP formulations by human acute monocytic leukemia cell line (THP1) after incubation for (a) 60, (b) 120 and (c) 240 min using FACS.	216
Figure 5.6	Phagocytic uptake of 6-coumarin loaded PCL and pegylated PCL NPs using Human acute monocytic leukemia cell line, THP-1 after incubation for 60, 120 and 240 min using FACS. Data presented as Mean ± SD, n=3.	217
Figure 5.7	Drug release profile of EXE from plain drug suspension, PCL NPs and pegylated PCL NPs across semi-permeable membrane using the dialysis bag diffusion technique in phosphate buffered saline (pH 7.4). The values represent mean ± S.D. of three batches.	218
Figure 5.8	TEM image of EXE loaded pegylated PCL ImmunoNPs.	219
Figure 6.1	Schematic presentation of principle for cell cycle analysis using DNA intercalating florescence probe in flow cytometry.	224
Figure 6.2	Receptor expression analyses in cell lines.	228
Figure 6.3	Quantitative intracellular uptake histograms of 6-Coumarin	229

	loaded PLGA NPs, pegylated PLGA NPs and ER antibody conjugated ImmunoNPs by MCF7 cells using flow cytometry.	
Figure 6.4	Quantitative intracellular uptake of 6-Coumarin loaded PLGA NPs, pegylated PLGA NPs and ER antibody conjugated ImmunoNPs by MCF7 cells using flow cytometry. Uptake was calculated by measuring MFI and represented as mean ± S.D. (n=3)	230
Figure 6.5	Quantitative intracellular uptake histograms of 6-Coumarin loaded PCL NPs, pegylated PCL NPs and ER antibody conjugated ImmunoNPs by MCF7 cells using flow cytometry.	231
Figure 6.6	Quantitative intracellular uptake of 6-Coumarin loaded PCL NPs, pegylated PCL NPs and ER antibody conjugated ImmunoNPs by MCF7 cells using flow cytometry. Uptake was calculated by measuring MFI and represented as mean ± S.D. (n=3)	231
Figure 6.7	Qualitative cellular uptake of PLGA NPs, pegylated PLGA and ImmunoNPs using fluorescent microscope. (A-C) ImmunoNPs; (D-F) pegylated PLGA NPs; (G-I) PLGA NPs; (J-L) 6-Coumarin dye solution; (B, E, H and K) nucleus stained using Hoechst 33342; (C, F, I and L) overlapping images.	232
Figure 6.8	Qualitative cellular uptake of PCL NPs, pegylated PCL NPs and ImmunoNPs using fluorescent microscope. (A-C) ImmunoNPs; (D-F) pegylated PCL NPs; (G-I) PCL NPs; (J-L) 6-Coumarin dye solution; (B, E, H and K) nucleus stained using Hoechst 33342; (C, F, I and L) overlapping images.	233
Figure 6.9	Cytotoxicity of ATZ loaded formulations (solution, PLGA NPs, PLGA PEG NPs, ImmunoNPs) and blank PLGA PEG NPs on MCF7 (A,B,C) and MDAMB231 (D,E,F) cells after exposure for 6 h (A, D), 24 h (B, E) and 48 h (C, F).	235
Figure 6.10	Cytotoxicity of ATZ loaded formulations (solution, PCL NPs,	236

PCL PEG NPs, ImmunoNPs) and blank PCL PEG NPs on MCF7 (A,B,C) and MDAMB231 (D,E,F) cells after exposure for 6 h (A, D), 24 h (B, E) and 48 h (C, F).

Figure 6.11 Cytotoxicity of EXE loaded formulations (solution, PLGA NPs, PLGA PEG NPs, ImmunoNPs) and blank PLGA PEG NPs on MCF7 (A,B,C) and MDAMB231 (D,E,F) cells after exposure for 6 h (A, D), 24 h (B, E) and 48 h (C, F). 238

Figure 6.12 Cytotoxicity of EXE loaded formulations (solution, PCL NPs, PCL PEG NPs, ImmunoNPs) and blank PCL PEG NPs on MCF7 (A,B,C) and MDAMB231 (D,E,F) cells after exposure for 6 h (A, D), 24 h (B, E) and 48 h (C, F). 239

Figure 6.13 Apoptosis estimation in MCF7 cell line after exposure of Control (PBS), A; ATZ Solution, B; ATZ PLGA NPs, C; ATZ PLGA-PEG NPs, D; and ATZ PLGA-PEG ImmunoNPs, E; for 24 and 48 h by Annexin V-FITC and PI staining using FACS technique. Necrotic cells FITC (-) PI (+), Late apoptosis FITC (+) PI (+), Live FITC (-) PI (-), Early apoptotis FITC (+) PI (-). 243

Figure 6.14 Apoptosis estimation in MCF7 cell line after exposure of Control (PBS), A; ATZ Solution, B; ATZ PCL NPs, C; ATZ PCL-PEG NPs, D; and ATZ PCL-PEG ImmunoNPs, E; for 24 and 48 h by Annexin V-FITC and PI staining using FACS technique. Necrotic cells FITC (-) PI (+), Late apoptosis FITC (+) PI (+), Live FITC (-) PI (-), Early apoptotis FITC (+) PI (-). 244

Figure 6.15 Apoptosis estimation in MCF7 cell line after exposure of Control (PBS), A; EXE Solution, B; EXE PLGA NPs, C; EXE PLGA-PEG NPs, D; and EXE PLGA-PEG ImmunoNPs, E; for 24 and 48 h by Annexin V-FITC and PI staining using FACS technique. Necrotic cells FITC (-) PI (+), Late apoptosis FITC (+) PI (+), Live FITC (-) PI (-), Early apoptotis FITC (+) PI (-). 245

Figure 6.16 Apoptosis estimation in MCF7 cell line after exposure of 246

	Control (PBS), A; EXE Solution, B; EXE PCL NPs, C; EXE PCL-PEG NPs, D; and EXE PCL-PEG ImmunoNPs, E; for 24 and 48 h by Annexin V-FITC and PI staining using FACS technique. Necrotic cells FITC (-) PI (+), Late apoptosis FITC (+) PI (+), Live FITC (-) PI (-), Early apoptotis FITC (+) PI (-).	
Figure 6.17	Effect of ATZ, ATZ PLGA PEG NPs and ImmunoNPs exposure on cell cycle distribution in MCF7 cells using FACS as an estimation technique.	247
Figure 6.18	Effect of ATZ, ATZ PCL PEG NPs and ImmunoNPs exposure on cell cycle distribution in MCF7 cells using FACS as an estimation technique.	248
Figure 6.19	Effect of EXE, EXE PLGA PEG NPs and ImmunoNPs exposure on cell cycle distribution in MCF7 cells using FACS as an estimation technique.	249
Figure 6.20	Effect of EXE, EXE PCL PEG NPs and ImmunoNPs exposure on cell cycle distribution in MCF7 cells using FACS as an estimation technique.	250
Figure 7.1	Biodistribution of ^{125}I labeled Tyrosine and ER antibody conjugated PLGA NPs and the radioactivity was measured after 3 and 24 h post injection. The values represented as mean ± SD. Radioactivity is expressed as percent of administered dose per gram of tissue or organ.	261
Figure 7.2	Biodistribution of ^{125}I labeled Tyrosine and ER antibody conjugated PCL NPs and the radioactivity was measured after 3 and 24 h post injection. The values represented as mean ± SD. Radioactivity is expressed as percent of administered dose per gram of tissue or organ.	264